Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet-Uro 19BEYOND study.
Roviello G, Gambale E, Giorgione R, Santini D, Stellato M, Fornarini G, Rebuzzi SE, Basso U, Bimbatti D, Doni L, Nesi G, Bersanelli M, Buti S, De Giorgi U, Galli L, Sbrana A, Conca R, Carella C, Naglieri E, Pignata S, Procopio G, Antonuzzo L. Roviello G, et al. Among authors: bimbatti d. Cancer Med. 2022 Aug;11(16):3084-3092. doi: 10.1002/cam4.4681. Epub 2022 Mar 20. Cancer Med. 2022. PMID: 35312175 Free PMC article.
Metabolic alterations in renal cell carcinoma.
Massari F, Ciccarese C, Santoni M, Brunelli M, Piva F, Modena A, Bimbatti D, Fantinel E, Santini D, Cheng L, Cascinu S, Montironi R, Tortora G. Massari F, et al. Among authors: bimbatti d. Cancer Treat Rev. 2015 Nov;41(9):767-76. doi: 10.1016/j.ctrv.2015.07.002. Epub 2015 Jul 9. Cancer Treat Rev. 2015. PMID: 26169313 Review.
Addressing the best treatment for non-clear cell renal cell carcinoma: A meta-analysis of randomised clinical trials comparing VEGFR-TKis versus mTORi-targeted therapies.
Ciccarese C, Iacovelli R, Brunelli M, Massari F, Bimbatti D, Fantinel E, De Marco V, Porcaro AB, Martignoni G, Artibani W, Tortora G. Ciccarese C, et al. Among authors: bimbatti d. Eur J Cancer. 2017 Sep;83:237-246. doi: 10.1016/j.ejca.2017.06.030. Epub 2017 Jul 27. Eur J Cancer. 2017. PMID: 28756136 Review.
Predictive role of changes in the tumor burden and International Metastatic Renal Cell Carcinoma Database Consortium class during active surveillance for metastatic renal cell carcinoma.
Bimbatti D, Ciccarese C, Fantinel E, Sava T, Massari F, Bisogno I, Romano M, Porcaro A, Brunelli M, Martignoni G, Mazzarotto R, Artibani W, Tortora G, Iacovelli R. Bimbatti D, et al. Urol Oncol. 2018 Dec;36(12):526.e13-526.e18. doi: 10.1016/j.urolonc.2018.08.018. Epub 2018 Oct 6. Urol Oncol. 2018. PMID: 30301699
Cabozantinib-related cardiotoxicity: a prospective analysis in a real-world cohort of metastatic renal cell carcinoma patients.
Iacovelli R, Ciccarese C, Fornarini G, Massari F, Bimbatti D, Mosillo C, Rebuzzi SE, Di Nunno V, Grassi M, Fantinel E, Ardizzoni A, Tortora G. Iacovelli R, et al. Among authors: bimbatti d. Br J Clin Pharmacol. 2019 Jun;85(6):1283-1289. doi: 10.1111/bcp.13895. Epub 2019 Mar 31. Br J Clin Pharmacol. 2019. PMID: 30740760 Free PMC article.
The prognostic value of pain in castration-sensitive prostate cancer.
Iacovelli R, Ciccarese C, Caffo O, De Giorgi U, Tucci M, Mosillo C, Bimbatti D, Pierantoni F, Maines F, Casadei C, Buttigliero C, Milella M, Tortora G. Iacovelli R, et al. Among authors: bimbatti d. Prostate Cancer Prostatic Dis. 2020 Dec;23(4):654-660. doi: 10.1038/s41391-020-0255-x. Epub 2020 Jul 10. Prostate Cancer Prostatic Dis. 2020. PMID: 32651468
68 results